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Introduction: Administration of several cardiovascular drugs has an effect on dementia. We aimed to investigate
whether there are differences in the use of cardiovascular medication between different dementia disorders.
Methods: We obtained information about dementia patients from the Swedish Dementia Registry. Patients were
diagnosed with one of these dementia disorders: Alzheimer’s disease (n = 8,139), mixed dementia (n = 5,203),
vascular dementia (n = 4,982), Lewy body dementia (n = 605), frontotemporal dementia (n = 409) and Parkinson’s
disease dementia (n = 405). Multivariate logistic regression analysis was performed to investigate the association
between use of cardiovascular medication and dementia disorders, after adjustment for age, gender, living alone,
cognitive status and total number of drugs (a proxy for overall co-morbidity).
Results: Seventy percent of all the dementia patients used cardiovascular medication. Use of cardiovascular drugs
is common in patients with vascular and mixed dementia. Male gender, higher age, slightly better cognitive status
and living with another person was associated with use of cardiovascular medication.
Conclusions: Cardiovascular medication is used extensively across dementia disorders and particularly in vascular
and mixed dementia. Future research should investigate the tolerability and effectiveness of these drugs in the
different dementia disorders.Introduction
Dementia is a devastating disease that is highly related
to age. Several cardiovascular (CV) disorders have been
suggested as risk factors for dementia, such as hyperten-
sion [1], hypercholesterolemia [2,3], atrial fibrillation [4]
and heart failure [5]. Correct management of these con-
ditions can slow down cognitive decline [6], reduce the
risk for dementia [7] and maintain stability in patients
with dementia [8]. Several CV drugs have been reported
to decrease the risk of developing dementia [7,9], to im-
prove cognition [10-12] or – on the contrary – to impair* Correspondence: Pavla.Cermakova@ki.se
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article, unless otherwise stated.cognition [13], independent from the effect of treating
CV diseases.
Treatment with antihypertensive medication was as-
sociated with a 50% reduction of dementia risk in the
trial Systolic Hypertension in Europe [14]. On the other
hand, The Study on Cognition and Prognosis in the Elderly
did not find any positive impact of antihypertensive treat-
ment on cognitive decline and dementia [15]. Antagonists
of the renin–angiotensin–aldosterone system, such as
angiotensin-converting enzyme inhibitors and angio-
tensin II receptor blockers, have recently gained inter-
est in the dementia field, because the renin–
angiotensin–aldosterone system is involved in several
major processes such as regulation of cerebral blood
flow, inflammation or memory consolidation [16-18].
Centrally active angiotensin-converting enzyme inhibitors
have been shown to protect against brain injury and to
slow down cognitive decline [6,19-21]. Angiotensin IItral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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reduction in the incidence and progression of dementia
compared with other CV drugs in a prospective cohort
analysis [22]. Clinical trials aimed to investigate the
impact of lipid-lowering drugs on dementia have not
been able to show a significant benefit on the reduction
of dementia risk [23].
Alzheimer’s disease (AD) is the most prevalent dementia
disorder and accounts for about two-thirds of dementia
cases [24]. The second most common type is vascular de-
mentia (VaD). Individuals with AD are often afflicted with
VaD, which is then named mixed dementia (MixD) [25].
There is a lack of reliable epidemiological data on the
prevalence of dementia with Lewy bodies (DLB), but this
is considered the third most common type [26,27]. DLB
often overlaps with Parkinson’s disease dementia (PDD)
[28]. Frontotemporal dementia (FTD) accounts for about
4 to 10% of all dementia subtypes [24].
AD patients used to be considered as the healthiest group
of dementia patients [29], since it has been reported that
AD is associated with fewer comorbidities compared
with the other dementia subtypes [30,31]. These results
are not in line with more recent papers that have reported
the opposite [32,33]. In a study by Imfeld and colleagues,
however, CV comorbidities and exposure to CV drugs
were significantly lower in AD patients, whereas the op-
posite result was found in VaD patients [29]. A recent
study on incident AD cases showed that 34% were treated
with more than five drugs [34].
The treatment of CV diseases or administration of CV
drugs may be negatively influenced by several conditions as-
sociated with dementia. Autonomic dysfunction is present
in all dementia disorders [35,36], particularly in DLB and
PDD [37], and complicates the management of blood pres-
sure. Furthermore, dysphagia in AD patients [38], living
alone [39] and a high level of cognitive impairment [40] can
cause problems with the administration of drugs.
There is an insufficient number of studies on compar-
isons between all different dementia disorders [41,42],
probably due to the lack of large patient material. This
study aims to investigate whether there are differences
in the use of CV medication between different dementia
disorders in a large population of dementia patients from
the Swedish Dementia Registry (SveDem). To our know-
ledge, SveDem includes the highest number of patients
with different dementia disorders worldwide.
Methods
Study population
We analyzed cross-sectional data from SveDem, which
is a national registry for improvement of the quality of
diagnostic workup, treatment and care of patients with
dementia in Sweden. This registry included 28,722 pa-
tients who were newly diagnosed with dementia eitherat a memory clinic or in a primary care unit from 2007 to
2012. Age, gender, demographic data, body mass index,
Mini Mental State Examination (MMSE) scores, diagnos-
tic procedures, type of dementia disorder and treatment
are recorded in this web-based registry.
Since 2009 SveDem has been monitored to ensure the
quality of the registered data. According to a recent annual
report, 76% of memory clinics are now under monitoring
[43]. Ten percent of the registrations at each unit are ran-
domly selected and checked with the data in the medical
records to see whether the data correspond.
Definitions
Dementia was diagnosed according to the International
Classification of Diseases version 10 [44]. In addition, DLB
was diagnosed based on the McKeith criteria [28] and the
Manchester criteria were used for the diagnosis of FTD
[45]. Unspecified dementia is diagnosed if the dementia
etiology is unknown or if investigations aimed to differen-
tiate the type of dementia have not been performed. Other
dementia types comprise rare dementia disorders that are
represented, for example, by corticobasal degeneration or
alcoholic dementia. The following dementia disorders are
included in SveDem: AD, VaD, MixD, LBD, FTD, PDD,
unspecified dementia and other types.
In SveDem, the following classes of drugs were registered
at the beginning of the diagnostic workup with the possible
answers ‘yes’/‘no’/‘do not know’: CV drugs, cholinesterase
inhibitors (ChEI), N-methyl-D-aspartate (NMDA) receptor
antagonists, antidepressants, anxiolytics, antipsychotics and
hypnotics/sedatives. The total number of prescribed drugs
was also recorded. The latter variable was used as a proxy
for overall comorbidity [46]. CV drugs comprised antihyper-
tensives, anticoagulants, lipid-lowering drugs, antidiabetics
and anti-angina medication. Living condition was reported
as living alone or living with another person. This informa-
tion was obtained from medical records and is therefore
based on the medical history received directly from patients
or indirectly; that is, from relatives or caregivers.
Only patients who were diagnosed with AD, VaD, MixD,
LBD, FTD and PDD were analyzed (n = 21,458). Patients
attributed to unspecified dementia or to other types were
not included in this study due to the imprecision of these
diagnostic groups. Also, patients with the answer ‘do not
know’ (8%) about CV medication were excluded from
this study. In total, 8,979 subjects were excluded from
the whole SveDem population.
Ethical issues
Patients and their relatives were informed orally and in
writing about SveDem and could decline participation.
The study was approved by the regional ethical review
board in Stockholm (Drn: 2013/147-31/2). The data
were anonymized before statistical analysis.
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Descriptive data are presented as the mean and standard
deviation. We checked the normality of distribution
using the Kolmogorov–Smirnov test. In cases of continuous
variables we used the independent sample t test or one-way
analysis of variance, and for categorical variables we used
the chi-square test. Multivariate analysis was performed
using binary logistic regression modeling to calculate odds
ratios (ORs) with 95% confidence intervals (CIs). Two-
tailed P < 0.05 was considered to be statistically significant
in all analytical procedures. Data were analyzed using the
Statistical Package for the Social Sciences software version
22 (IBM Corporation, Armonk, NY, USA).
Results
A total of 19,743 incident dementia patients were included
in this study. Their characteristics are presented in Table 1.
There were 11,537 women (58%) and 8,206 men (42%).
The mean age of the patients at the time of diagnosis was
78.9 ± 7.8 years and the mean MMSE score was 21 ± 5.
AD was the most common dementia disorder in the
study population (41%). MixD accounted for 27% and
VaD for 25% of all dementia subtypes. Other types rep-
resented a minority (DLB, 3%; FTD, 2%; and PDD, 2%).
Patients diagnosed with MixD were the oldest (mean
age 81.0 ± 6.5 years), while those with FTD represented
the youngest group with a mean age of 70.0 ± 10.0 years.Table 1 Characteristics of the dementia patients, Swedish De
Total AD MixD
(n = 19,743) (n = 8,139; 41%) (n = 5,203; 27
Age
Mean 78.9 ± 7.8 77.7 ± 8.1 81.0 ± 6.5
Range 27 to 103 27 to 99 52 to 100
Gender, n (%)
Female 11,537 5,328 3,075
(58.0%) (65.5%) (59.1%)
Male 8,206 2,811 2,128
(42.0%) (34.5%) (40.9%)
MMSE
Mean 21.3 ± 5.0 21.6 ± 5.0 21.0 ± 5.0
Range 0 to 30 0 to 30 0 to 30
Living alone (%) 44.3 43.0 48.7
CV drugs (%) 70.0 59.4 76.9
ChEIs (%) 49.8 73.0 53.9
NMDA antagonists (%) 10.5 9.8 17.0
Number of drugs
Mean 5.0 ± 3.1 4.0 ± 2.8 5.4 ± 3.1
Range 0 to 24 0 to 21 0 to 24
AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; CV, cardiovascular; DLB, dem
MMSE, Mini Mental State Examination; NMDA, N-methyl-D-aspartate; PDD, ParkinsoThe mean MMSE score varied between 21 ± 5 in the
group of MixD and 24 ± 5 in FTD patients.
Figure 1 illustrates the distribution of various types of
dementia in different age groups in the study population.
The proportion of VaD ranged from 12 to 20.4% in dif-
ferent age groups and a gradual increase was observed
from the youngest group (≤64 years) to the group 85 to
89 years old. The rate of patients diagnosed with AD de-
creased steadily from 46.1% in the ≤64 year group to
21.8% among those who were older than 90 years at the
time of diagnosis. Moreover, as shown in Figure 1, the
relative frequency of an unspecified type of dementia in-
creased from 14.3% to as high as 36.6% in the oldest
group. The proportion of patients diagnosed with VaD
increased from 13.2% in 2007 to 20.1% in 2012 during
the registration period (Figure 2). An opposite trend
could be seen for the AD diagnosis, where the rate de-
creased from 42.7% to 26.8% from 2007 to 2012.
Seventy percent of the population used CV drugs. These
drugs were least common among AD patients (59%) and
most common among VaD patients (84%). ChEIs were
prescribed to 50% of patients and they were used most by
AD patients (73%) and least by FTD patients (7%). On the
other hand, NMDA antagonists were largely used in MixD
(17%) and only seldom in VaD (5%). The mean number
of prescribed drugs ranged from 3.7 ± 2.8 in FTD patients
to 6.5 ± 3.2 in PDD patients.mentia Registry 2007 to 2012
VaD DLB FTD PDD
%) (n = 4,982; 25%) (n = 605; 3%) (n = 409; 2%) (n = 405; 2%)
80.0 ± 7.4 76.5 ± 7.1 70.0 ± 10.0 75.2 ± 7.0
33 to 103 53 to 94 39 to 96 49 to 94
2,514 236 228 156
(50.5%) (39.0%) (55.7%) (38.5%)
2,468 369 181 249
(49.5%) (61.0%) (44.3%) (61.5%)
21.2 ± 4.9 21.5 ± 5.0 23.6 ± 5.0 21.0 ± 5.1
0 to 30 0 to 30 3 to 30 6 to 30
45.7 34.7 33.0 22.7
84.3 59.5 53.3 57.5
7.8 74.4 6.8 54.6
4.7 15.0 4.9 11.6
6.2 ± 3.2 4.8 ± 2.9 3.7 ± 2.8 6.5 ± 3.2
0 to 23 0 to 17 0 to 13 0 to 19
entia with Lewy bodies; FTD, frontotemporal dementia; MixD, mixed dementia;
n’s disease dementia; VaD, vascular dementia.
Figure 1 Proportion of various types of dementia in different age groups in patients registered in the Swedish Dementia Registry
during 2007 to 2012. AD, Alzheimer’s disease; yr, year.
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used CV drugs and those who did not. Patients with CV
medications were older and had a slightly higher MMSE
score compared with those who were not treated with CV
drugs. The use of ChEIs was higher among patients whoFigure 2 Frequency of different types of dementia in patients registe
each registration year. AD, Alzheimer’s disease.did not receive CV medication, while the opposite was
found for NMDA antagonists.
In the adjusted logistic regression analysis (Table 3) we
found that male gender correlated with a higher probabil-
ity of using CV medication when compared with womenred in the Swedish Dementia Registry during 2007 to 2012 within
Table 2 Characteristics of patients with and without









Mean 79.6 ± 7.2 77.4 ± 8.9
<0.001
Range 33 to 103 27 to 97
Gender
Female (%) 55.9 64.4
<0.001
Male (%) 44.1 35.6
MMSE
Mean 21.4 ± 4.9 21.3 ± 5.2
<0.001
Range 0 to 30 0 to 30
Living alone (%) 43.7 45.7 0.006
ChEIs (%) 46.1 58.5 <0.001
NMDA antagonists (%) 10.6 10.3 0.028
Number of drugs
Mean 5.8 ± 3 3,0 ± 2.5
<0.001
Range 0 to 24 0 to 21
AD (%) 34.9 56.0 <0.001
MixD (%) 28.9 20.4 <0.001
VaD (%) 30.3 13.2 <0.001
DLB (%) 2.6 4.2 <0.001
FTD (%) 1.6 3.2 <0.001
PDD (%) 1.7 2.9 <0.001
AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; CV, cardiovascular; DLB,
dementia with Lewy bodies; FTD, frontotemporal dementia; MixD, mixed
dementia; MMSE, Mini Mental State Examination; NMDA, N-methyl-D-aspartate;
PDD, Parkinson’s disease dementia; VaD, vascular dementia.
Table 3 Adjusted odds ratios for characteristics of
patients with cardiovascular drugs compared to persons
without cardiovascular medication, Swedish Dementia
Registry 2007 to 2012
Patients with CV medication (n = 13,847)
Age 1.02 (1.01 to 1.02)*
Male gender 1.45 (1.34 to 1.57)*
MMSE 1.02 (1.01 to 1.03)*
Living alone 0.75 (0.69 to 0.81)*
ChEIs 1.08 (0.98 to 1.19)
NMDA antagonists 0.98 (0.85 to 1.12)
Total number of drugs 1.53 (1.50 to 1.56)*
Dementia disorder
AD Reference
MixD 1.57 (1.43 to 1.73)*
VaD 2.14 (1.89 to 2.44)*
DLB 0.71 (0.58 to 0.87)*
FTD 0.91 (0.71 to 1.17)
PDD 0.31 (0.24 to 0.40)*
Age, MMSE and total number of drugs were analyzed as continuous variables.
Odds ratios with 95% confidence interval adjusted for all variables in this
table. AD, Alzheimer’s disease; ChEI, cholinesterase inhibitor; CV,
cardiovascular; DLB, dementia with Lewy bodies; FTD, frontotemporal
dementia; MixD, mixed dementia; MMSE, Mini Mental State Examination;
NMDA, N-methyl-D-aspartate; PDD, Parkinson’s disease dementia; VaD, vascular
dementia. *Statistically significant at the level of P < 0.001.
Cermakova et al. Alzheimer's Research & Therapy 2014, 6:34 Page 5 of 9
http://alzres.com/content/6/3/34(adjusted OR = 1.45; 95% CI = 1.34 to 1.57). Living alone
was associated with lower use of CV drugs (adjusted
OR = 0.75, 95% CI = 0.69 to 0.81). Higher age and
higher MMSE score were slightly related to the use of
CV medication. There were no differences in the use of
dementia medication between the patients with CV
drugs and those without them. VaD showed the stron-
gest association with use of CV drugs when compared
with AD (adjusted OR = 2.14; 95% CI = 1.89 to 2.44).
The probability of receiving CV medication was also sig-
nificantly higher in MixD (adjusted OR = 1.57; 95% CI =
1.43 to 1.73). DLB and PDD patients were less likely to
receive CV medication, while the difference between
FTD and AD was not significant.
Discussion
Main findings
In our study of 19,743 dementia patients, AD was the most
common dementia disorder, followed by MixD and VaD.
DLB, FTD and PDD were less common. In the population
of patients diagnosed with a dementia disorder, the overalluse of CV drugs was 70%. Another study that investigated
drug use in older persons in Sweden found that 66% of
them used CV medication [47]. In a population-based
study performed in Finland, the proportion of older persons
who used CV medicines reached 86% [48]. The prevalence
of CV drugs was above 50% in all of the dementia disor-
ders. As expected, CV drugs were the most common in
patients diagnosed with VaD (84%) followed by MixD
(77%). However, the overall high use of CV medication
in AD, DLB, FTD and PDD implies that these patients
also suffer from CV diseases to a great extent. Our find-
ing that AD patients seemed to have comparably less
CV comorbidities may be biased by the fact that demen-
tia patients with CV comorbidities are more likely to be
diagnosed with VaD or MixD than with AD. The rela-
tionship between CV diseases and AD is complex and
may be influenced not only by CV medication, but also
by anti-dementia medication such as ChEI. We have re-
cently shown, using data from the SveDem registry, that
treatment with ChEI in AD patients was associated with
a reduced risk for myocardial infarction and death [49].
The burden of CV diseases in PDD is clinically relevant,
especially in relation to treatment of Parkinson’s disease.
Some dopamine agonists are associated with a worse CV
profile [50] and increased risk for heart valvular fibrosis
[51,52]. We observed a very high total number of drugs in
PDD patients (6.5 ± 3.2). This is consistent with previous
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a higher number of comorbidities compared with the gen-
eral population [53]. However, PDD patients were signifi-
cantly less likely to receive treatment with CV drugs when
compared with AD patients. The DLB patients in our
study population had a lower level of overall comorbidity.
There is a lack of studies about the significance of CV
diseases in DLB patients [54], but history of stroke has
been reported to occur more often in DLB patients
than in controls [55]. The relatively lower use of CV
drugs in PDD and DLB patients compared with AD
may be attributed to the fear of their side effects and
difficulties in the management of blood pressure due to
autonomic dysfunction [37].
Patients diagnosed with FTD represent the youngest
group of dementia patients. They also seemed to have the
least CV comorbidities, but after adjustment for age and
other confounders they had a similar probability of receiv-
ing CV medication as AD patients (adjusted OR = 0.91;
95% CI = 0.71 to 1.17). This confirms an already known
relationship between advanced age and a higher
amount of comorbidities [56].
One study has suggested that men suffering from de-
mentia have a higher level of comorbidities [57]. Our
investigation confirms this finding as male gender was
associated with the use of CV drugs. However, this
seems to be specific for CV medication, because older
women use more medicines in general than older men
[58-60]. Persons using CV drugs were found to have a
lower probability of living alone, which could indicate
that living alone would be associated with better CV
health. However, people who live alone may not seek
medical treatment or may have inadequate compliance
with drug treatment. Indeed, it has been shown that
living with another person is associated with increased
adherence to medication [61]. There are gender differences
regarding living conditions in older people. Older men are
more likely to live at home while older women are more
often institutionalized [62]. This could be explained by
differences in social and marital conditions between older
men and older women [63,64] as well as by the fact that
older women experience more disabilities compared with
men [57]. In another investigation that compared medica-
tion in institutionalized and community-dwelling older
people, institutionalization was found to be negatively
associated with the use of many CV drugs [65].
Strengths and limitations
The findings of this study are strengthened by a large
sample of patients from several parts of Sweden and dif-
ferent dementia subtypes. Compared with drug registry-
based studies that use medicines prescribed to patients,
our study may reflect the reality by having information
about the drug treatment obtained directly from patientsor their relatives. This study is cross-sectional; thus we
cannot conclude any causal relationships. However, pa-
tients in SveDem are followed-up, which opens up pos-
sibilities for longitudinal studies in the future.
We did not include persons who were attributed to
unspecified or other types of dementia (n = 7,264; mean
age 80.6 ± 8.1; mean MMSE 20.5 ± 5.2). Furthermore, in
SveDem there is a possibility to respond with the answer
‘do not know’, which led to missing values for our data
on CV medication and the necessity to exclude 8% of
patients from the study. The persons excluded due to
missing values differed from the study population in
their mean age (77.6 ± 9.1 vs. 78.9 ± 7.8; P < 0.001) and
MMSE score (21.0 ± 5.8 vs. 21.3 ± 5.0; P < 0.001), which
could have introduced selection bias.
Patients at 58 memory clinics from all Sweden hospi-
tals and from local to university hospitals were included.
In the last year, the number of patients diagnosed in pri-
mary care units has significantly increased in SveDem
and even more primary care units will be affiliated in the
future. The reliability of the data in SveDem has been
validated, especially in memory clinics. There is still a
lower number of primary care units where the quality of
registered data is monitored [43]. The data registered in
memory clinics in a random sample of patients were in
good agreement with medical records in a reliability test
[66]. The validity of the diagnosis of dementia disorders
has not been examined.
Considering the coverage of SveDem, our study could
not provide incidence rates of dementia for the entire
Swedish population. The incidence rate of dementia in
Sweden is estimated to be about 24,000 new cases annually
[67] and, considering the fact that nearly 8,000 newly
diagnosed dementia patients are registered each year
in SveDem, an overall coverage rate of 33% could be
assumed. A recent study showed a prevalence rate of
17 to 18% in the Swedish population aged >75 years
using data from two cohorts [68]. The study also con-
cluded that the incidence of dementia might have de-
creased over the two recent decades. With regard to
the frequency of various types of dementia within dif-
ferent age strata, our findings showed that the propor-
tions of dementia patients diagnosed with VaD and
unspecified dementia are increasing by age. Another
previous report from Sweden claimed that VaD con-
tributed to one-quarter of all dementias [69], which
was found to be almost one-fifth or less in our study.
However, in this previous survey there was no MixD
included, which could have led to a higher incidence
for VaD. In line with this previous report [69], we also
showed that the proportion of unspecified dementia
was increasing among the older age groups. Further-
more, a steady increase was observed in the proportion
of VaD in our study population over time during the
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data from both primary care units and memory clinics, the
simultaneous increase in the number of primary care units
and older age of registered patients might have contributed
to this increase in the proportion of VaD over time.
Conclusion
CV medication is used extensively across dementia disor-
ders, and particularly in VaD and MixD. Future research
should investigate the tolerability and effectiveness of these
drugs in the different dementia disorders.
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